Drug Profile


Alternative Names: BG 9719; CVT 124

Latest Information Update: 23 Aug 2002

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Florida; University of South Florida
  • Developer Biogen; CV Therapeutics; University of Florida; University of South Florida
  • Class Small molecules; Xanthines
  • Mechanism of Action Adenosine A1 receptor antagonists; Diuretics
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Heart failure; Hypertension

Most Recent Events

  • 23 Aug 2002 CVT 124 is now called Naxifylline
  • 29 Aug 2000 Discontinued-I for Hypertension in USA (IV)
  • 29 Aug 2000 Discontinued-II for Congestive heart failure in Europe (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top